Amanta Healthcare IPO:The stock market is buzzing once again, and this time all eyes are on Amanta Healthcare’s ₹126 crore IPO, which has captured strong attention from investors across India. With over 6 times subscription on just the second day, the issue has turned into a hot topic in Dalal Street circles. Retail investors, in particular, have shown overwhelming interest, keeping hopes high for solid listing gains.
Grey Market Premium Shows Steady Optimism
Even though the Grey Market Premium (GMP) has slipped slightly to 12% from earlier levels, it still signals healthy listing expectations. For many investors, this unofficial indicator serves as a glimpse of market sentiment before the stock officially debuts on the exchanges.
Retail Investors Take Center Stage
Among all investor categories, retail participants have stolen the spotlight by subscribing nearly 9 times their quota, reflecting strong trust in the company’s growth story. High net worth individuals (HNIs) too have shown solid interest, while institutional buyers are expected to step in more actively as the IPO nears closure.
A Glimpse Into Amanta Healthcare’s Business
Headquartered in Ahmedabad, Amanta Healthcare is known for its expertise in sterile injectables, IV fluids, ophthalmic solutions, respiratory care, and medical devices. With a strong domestic network of 320+ distributors and a growing presence in Africa, Latin America, and the UK, the company has established itself as a trusted name in the healthcare space.
Its cutting-edge technologies like SteriPort (ISBM) and ABFS (Aseptic Blow-Fill-Seal) give it an edge in producing high-quality sterile products. The Hariyala facility in Gujarat, with seven advanced production lines, is certified by both Indian and global regulators.
Financial Performance Brings Confidence
In FY25, Amanta Healthcare reported revenues of ₹274.7 crore, slightly lower than the previous year’s ₹280.3 crore. However, what stood out was the jump in profitability the company’s profit after tax rose to ₹10.5 crore, nearly tripling from ₹3.6 crore in FY24. This strong margin improvement highlights operational efficiency and growth potential.
IPO Proceeds to Power Expansion
Funds raised from the IPO will be channelled into expanding SteriPort manufacturing lines and setting up a new production line for Small Volume Parenterals (SVPs). The remaining capital will support general corporate needs, strengthening Amanta’s foundation for future growth.
Should Investors Subscribe?
Market experts believe Amanta Healthcare is well placed in a niche yet growing segment. With rising demand for sterile pharmaceuticals, robust certifications across 120+ jurisdictions, and a wide product portfolio, the company is seen as a promising player. At an upper band valuation of around 47 times FY25 earnings, the pricing is considered fair for a company with long term growth potential.
For investors seeking to ride India’s expanding healthcare and pharmaceutical growth wave, this IPO offers an opportunity worth considering.
Disclaimer:This article is for information and educational purposes only. It should not be considered as financial advice or a recommendation to invest. Investors are advised to consult their financial advisors before making any investment decisions.
Also read: Modi Meets Xi: India Signals a New Era of Cooperation Ahead of SCO Summit
